Repligen corp stock

Nov 13, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.

Repligen Corporation Common Stock (RGEN) Stock Price, Quote, News & History | Nasdaq MY QUOTES: RGEN Edit my quotes Repligen Corporation Common Stock (RGEN) 0 Add to Watchlist... See the latest Repligen Corp stock price (RGEN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.11.55%. Overview. Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis.Find real-time RGEN - Repligen Corp stock quotes, company profile, news and forecasts from CNN Business.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Oct 12, 2021. The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop ...

Repligen Corp. (NASDAQ:RGEN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in ...Repligen Corp ( RGEN) receives a weak valuation ranking of 32 from InvestorsObserver data analysis. The proprietary ranking system focuses on the underlying health of a company through analysis of its stock price, earnings, and growth rate. RGEN has a better value than 32% of stocks based on these valuation analytics.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 24.63% in the past year. Currently, Repligen Corp’s price-earnings ratio is 60.3. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Stock Superstars Report Get stock ideas inspired by the market's leading professionals; VMQ Stocks For the value investor looking to harness academic research in an actively managed portfolio; All premium products come with free basic membership.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Oct 12, 2021. The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop ...

The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, …The stock of Repligen Corp. (NASDAQ: RGEN) has increased by 2.04 when compared to last closing price of 157.00. Despite this, the company has experienced a 2.74% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-11-07 that WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN ...A high-level overview of Repligen Corporation (RGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Repligen Corp’s ( RGEN) price is currently down 7.18% so far this month. During the month of September, Repligen Corp’s stock price has reached a high of $179.27 and a low of $159.54. Over the last year, Repligen Corp has hit prices as high as $235.06 and as low as $134.64. Year to date, Repligen Corp’s stock is down 39.05%.

Top meme stocks.

Repligen Corp stock has a Value Score of 5, Momentum Score of 54 and Estimate Revisions Score of 37. Comparing Agiliti Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 2.91% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.0. Repligen Corp’s trailing 12-month revenue is $801.3 million with a 20.8% net profit margin. Year-over-year quarterly sales growth most recently was 12.6%.Nov 13, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%. Nov 15, 2023 · On November 14, 2023, Repligen Corporation (NASDAQ:RGEN) stock closed at $153.79 per share. One-month return of Repligen Corporation (NASDAQ:RGEN) was 7.92%, and its shares lost 19.47% of their ... Repligen Corporation Common Stock (RGEN) Stock Price, Quote, News & History | Nasdaq MY QUOTES: RGEN Edit my quotes Repligen Corporation Common Stock (RGEN) 0 Add to Watchlist...Repligen Corp’s trailing 12-month revenue is $801.5 million with a 23.2% net profit margin. Year-over-year quarterly sales growth most recently was 0.2%. Analysts expect adjusted earnings to reach $2.678 per share for the current fiscal year. Repligen Corp does not currently pay a dividend. How We Compare DexCom, Inc. and Repligen Corp Stock ...

CureVac N.V. -0.54%. $1.23B. RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Nov 1, 2023 · The stock price rose by $0.27, resulting in a percentage change of +0.61%. While this may seem like a small change, it indicates positive momentum for the company’s stock. Looking ahead, Repligen Corporation is scheduled to release its next financial report on February 15, 2024. Get the latest Repligen Corporation (RGEN) stock news and headlines to help you in your trading and investing decisions. ... Raising target price to $161.00REPLIGEN CORP has an ... Nov. 14, 2023 ...On Friday, Repligen Corp (RGEN:NSQ) closed at 161.78, -19.50% below its 52-week high of 200.98, set on Feb 16, 2023. Data delayed at least 15 minutes, as of Nov 24 2023 18:00 GMT. Latest Repligen Corp (RGEN:NSQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and …On October 17, 2023, Repligen Corp (RGEN) stock showed promising performances, with a median target price forecast of $195.00 by 13 analysts. This represents a potential increase of 33.96% from the last recorded price of $145.57. The high estimate for the stock price is $240.00, while the low estimate is $165.00.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.As of February 22, 2023, Repligen Corp had a $9.9 billion market capitalization, compared to the Medical Equipment, Supplies & Distribution median of $330.1 million. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 5.92% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.8.Die Repligen Corp. Aktie wird unter der ISIN US7599161095 an den Börsen Frankfurt, Düsseldorf, München, Stuttgart, Berlin, NASDAQ, Bats, BX World, NASDAQ Bsc, Gettex, Tradegate, Lang & Schwarz ...www .repligen .com. Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. 2014 The company is based in Waltham, Massachusetts, 2014 and incorporated in Delaware in 1981. [1] A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. [2]Repligen Corp. (US:RGEN) has 1047 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 71,198,355 shares.RGN:MUN Munich Stock Exchange; RGN:STU Stuttgart Stock Exchange; RGEN:DEU German Composite; RGN:FRA Frankfurt Stock Exchange; RGN:DUS Dusseldorf Stock Exchange; ... Repligen Corp BUILDING 1, SUITE 100, 41 SEYON STREET WALTHAM 02453 United States USA; Phone +1 (781) 449-9560; Fax +1 (302) …

Repligen Announces Publication of the Company’s 2022 Sustainability Report November 14, 2023TipRanks. Repligen price target lowered to $150 from $165 at Deutsche Bank November 7, 2023TipRanks ...

Sep 18, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. The number of shares of the Company's common stock, $0.01 par value per share ("Common Stock"), entitled to vote at the Annual Meeting was 55,429,107. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 51,525,212, representing 92.96% of the total number of shares of Common Stock entitled to vote ...Repligen Corp’s ( RGEN) price is currently down 11.17% so far this month. During the month of April, Repligen Corp’s stock price has reached a high of $182.42 and a low of $149.02. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 43.53%.Repligen has a market cap of $14.2 billion, while Catalent is valued at $20.2 billion. RGEN shares are down year-to-date through Wednesday, while CTLT has dropped 12%.Stock Superstars Report Get stock ideas inspired by the market's leading professionals; VMQ Stocks For the value investor looking to harness academic research in an actively managed portfolio; All premium products come with free basic membership.The stock’s lowest price was $157.58 before closing at $157.00. Repligen Corp. experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $200.98 on 02/16/23, while the lowest price for the same period was registered at $110.45 on 10/30/23.When you start a small business, you’ll have many decisions to make. The process involves everything from choosing a business model and designing your marketing materials to hiring employees and setting prices.Repligen Corporation acquired Metenova AB for $173 million. Oct. 01: CI Repligen to Acquire Fluid Management Company Metenova Sep. 26: MT Repligen Corporation entered into a definitive agreement to acquire Metenova AB …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp., the recipient of this investment, is a global life sciences company specializing in providing bioprocessing technologies and solutions used in manufacturing biological drugs. ... While Repligen’s stock opened at $156.63 on Friday, the company had a market capitalization of $8.72 billion, with a beta of 1.08, and PE ratio of …

Nickels worth money 1964.

Un secured credit card.

Repligen Corp., the recipient of this investment, is a global life sciences company specializing in providing bioprocessing technologies and solutions used in manufacturing biological drugs. ... While Repligen’s stock opened at $156.63 on Friday, the company had a market capitalization of $8.72 billion, with a beta of 1.08, and PE ratio of …Dec 2, 2023 · With Repligen stock trading at $164.94 per share, the total value of Repligen stock (market capitalization) is $9.21B. Repligen stock was originally listed at a price of $0.78 in Dec 31, 1997 . If you had invested in Repligen stock at $0.78 , your return over the last 25 years would have been 21,019.08% , for an annualized return of 23.88% (not ... Inspire Medical Systems Inc. 151.72. +6.41. +4.41%. Get Repligen Corp (RGEN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.To be eligible to participate in a Job Corps program, applicants must qualify for low-income status under one of five income-related standards: cash assistance, food assistance, earned income, foster child and homelessness.Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for ...Stock Price Forecast The 13 analysts offering 12-month price forecasts for Repligen Corp have a median target of 170.00, with a high estimate of 210.00 and a low estimate of 148.00.Find real-time RGEN - Repligen Corp stock quotes, company profile, news and forecasts from CNN Business.Fundamentals REPLIGEN CORP. DL-,01. Dividend. Dividend yield in %. P/E Ratio. Profit per share. Number of shares. Market capitalization. News about REPLIGEN ... ….

Nov 29, 2023 · CI. Repligen Insider Sold Shares Worth $557,328, According to a Recent SEC Filing. Nov. 13. MT. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07. MT. CORRECTION : RBC Trims Price Target on Regeneron Pharmaceuticals to $837 From $847, Keeps Sector Perform Rating. Nov. 03. Repligen Corp Stock Price History. Repligen Corp’s price is currently down 7.01% so far this month. During the month of September, Repligen Corp’s stock price has reached a high of $179.27 and a low of $156.92. Over the last year, Repligen Corp has hit prices as high as $225.62 and as low as $134.64. Year to date, Repligen Corp’s stock is ...Repligen's (RGEN) third-quarter earnings and revenues surpass estimates. The company tightens revenue guidance for 2023. Shares rise. Get the latest Repligen Corporation …RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Repligen Corp’s ( RGEN) price is currently down 7.18% so far this month. During the month of September, Repligen Corp’s stock price has reached a high of $179.27 and a low of $159.54. Over the last year, Repligen Corp has hit prices as high as $235.06 and as low as $134.64. Year to date, Repligen Corp’s stock is down 39.05%.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 10.83% in the past year. Currently, Repligen Corp’s price-earnings ratio is 50.0. Repligen Corp’s trailing 12-month revenue is $801.5 million with a 23.2% net profit margin. Year-over-year quarterly sales growth most recently was 0.2%.Nov 30, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.08% in the past year. Currently, Repligen Corp’s price-earnings ratio is 78.5. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%. A high-level overview of Repligen Corporation (RGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.To be eligible to participate in a Job Corps program, applicants must qualify for low-income status under one of five income-related standards: cash assistance, food assistance, earned income, foster child and homelessness.The current consensus among 14 polled investment analysts is to buy stock in Repligen Corp. This rating has held steady since August, indicating a consistent belief in the company’s potential for growth. Repligen Corp has reported strong financials for the current quarter, with earnings per share of $0.55 and sales of $179.5 million. Repligen corp stock, [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1]